spacer
home > > autumn 2008 > future functions
PUBLICATIONS


Future Functions

It is nearly 20 years since the first commercial imaging core laboratory was founded. Today, there are numerous commercial imaging core laboratories, numerous international imaging biomarker meetings and regulatory guidance documents to support the use of imaging in drug development. Many academic, government and commercial entities have contributed to the growth of this approach, which has become a mainstream tool for the development of numerous therapeutic drugs.

Medical imaging endpoints are accepted in many clinical trials, and when included in the study design, the FDA requires the implementation of a central, independent image review process. The proliferation of medical imaging endpoints and the resulting management, analysis and submission of medical imaging data has fostered the healthy growth of the medical imaging core lab industry, both for commercial and academic labs. The increase in the number of labs and studies for which they provide services led to a somewhat varied set of documentation and implementation of various technology methods for what is a largely consistent undertaking. Pharmaceutical trial sponsors and the FDA initiated the desire for standardisation in these trials, and DIA has provided the leadership needed to obtain collaboration from all affected parties.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
James Conklin is the Senior Vice President for medical and scientific affairs at ICON Medical Imaging. James is a John Hopkins-trained research physician with undergraduate and graduate training in electrical/computer engineering and a Masters degree in Management. He has been a Professor of Radiology at several medical schools, published over 100 scientific papers and edited four books. One of the textbooks, Imaging Techniques in Biology and Medicine, published by Academic Press in 1987, provided the technical foundation for Bio-Imaging Technologies, Inc. He is board certified in both internal medicine and nuclear medicine.
spacer
James Conklin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement